Treating Hyperuricemia: The Last Word Hasn't Been Said Yet.
chronic kidney disease
hyperuricemia
urate lowering treatment
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
17 Feb 2021
17 Feb 2021
Historique:
received:
04
01
2021
revised:
07
02
2021
accepted:
15
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
7
3
2021
Statut:
epublish
Résumé
Gout as well as asymptomatic hyperuricemia have been associated with several traditional cardiovascular risk factors and chronic kidney disease. Both in vitro studies and animal models support a role for uric acid mediating both hemodynamic and tissue toxicity leading to glomerular and tubule-interstitial damage, respectively. Nevertheless, two recent well designed and carried out trials failed to show the benefit of allopurinol treatment on kidney outcomes, casting doubts on expectations of renal protection by the use of urate lowering treatment. With the aim of providing possible explanations for the lack of effect of urate lowering treatment on chronic kidney disease progression, we will critically review results from all available randomized controlled trials comparing a urate-lowering agent with placebo or no study medication for at least 12 months and report renal clinical outcomes.
Identifiants
pubmed: 33671406
pii: jcm10040819
doi: 10.3390/jcm10040819
pmc: PMC7922319
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Am J Kidney Dis. 2018 Mar;71(3):362-370
pubmed: 29132945
Ann Intern Med. 2020 Feb 4;172(3):186-194
pubmed: 31931526
Am J Nephrol. 2017;46(4):315-322
pubmed: 29032376
Ren Fail. 2019 Nov;41(1):616-622
pubmed: 31269852
Nutr Metab Cardiovasc Dis. 2014 Aug;24(8):921-7
pubmed: 24675005
Eur Heart J. 2019 Jun 7;40(22):1778-1786
pubmed: 30844048
Hypertension. 2016 May;67(5):934-40
pubmed: 27021006
Clin J Am Soc Nephrol. 2020 Nov 6;15(11):1576-1586
pubmed: 33055192
N Engl J Med. 2020 Jun 25;382(26):2504-2513
pubmed: 32579811
N Engl J Med. 2020 Jun 25;382(26):2493-2503
pubmed: 32579810
Kidney Int. 2004 Oct;66(4):1465-70
pubmed: 15458439
Curr Med Chem. 2020;27(30):5056-5066
pubmed: 30526453
Sci Rep. 2017 Jan 13;7:39884
pubmed: 28084303
Am J Hypertens. 2009 Feb;22(2):191-6
pubmed: 19151691
Nutr Metab Cardiovasc Dis. 2020 Nov 27;30(12):2343-2350
pubmed: 32912790
Clin Exp Nephrol. 2014 Dec;18(6):876-84
pubmed: 24448692
Am J Kidney Dis. 2006 Jan;47(1):51-9
pubmed: 16377385
Circulation. 2003 Jan 28;107(3):416-21
pubmed: 12551865
J Hypertens. 2008 Feb;26(2):269-75
pubmed: 18192841
Curr Opin Nephrol Hypertens. 2020 Jul;29(4):423-431
pubmed: 32452918
Diabetes Obes Metab. 2018 Feb;20(2):458-462
pubmed: 28846182
Hypertension. 2011 Jul;58(1):2-7
pubmed: 21632472
Circulation. 2002 Jun 4;105(22):2619-24
pubmed: 12045167
Am J Kidney Dis. 2015 Apr;65(4):543-9
pubmed: 25595565
Clin J Am Soc Nephrol. 2017 Apr 3;12(4):577-584
pubmed: 28153936
Clin J Am Soc Nephrol. 2010 Aug;5(8):1388-93
pubmed: 20538833
J Nephrol. 2020 Aug;33(4):715-724
pubmed: 31933161
Diabetes Care. 2018 Feb;41(2):356-363
pubmed: 29203583
Clin J Am Soc Nephrol. 2015 Nov 6;10(11):1921-9
pubmed: 26342044
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
JAMA. 2008 Aug 27;300(8):924-32
pubmed: 18728266
Int J Clin Pharmacol Ther. 2020 Jan;58(1):21-28
pubmed: 31657714
Biomed Rep. 2017 Oct;7(4):325-330
pubmed: 28928970
PLoS One. 2017 Jan 20;12(1):e0170393
pubmed: 28107415
Circ J. 2013;77(8):2043-9
pubmed: 23676888
Clin Endocrinol (Oxf). 2015 Oct;83(4):475-82
pubmed: 25400252
Hypertension. 2020 Feb;75(2):302-308
pubmed: 31813345
Clin Rheumatol. 2020 Nov;39(11):3287-3294
pubmed: 32418037
Clin Exp Nephrol. 2018 Aug;22(4):860-870
pubmed: 29372470
Am J Kidney Dis. 2018 Dec;72(6):798-810
pubmed: 30177485
Ann Intern Med. 2006 Feb 7;144(3):172-80
pubmed: 16461961